Recent Updates
Recently added Catalysts
CAMP Positive Sentiment

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: CAMP4 Therapeutics announced the grant of non-qualified stock options to two new employees on November 16, 2026. Each grant consists of 30,000 shares at an exercise price of $3.86, equal to the stock's closing price on the grant date. The options will vest over four years, promoting employee retention.

Market Sentiment Analysis

POSITIVE FACTORS

  • CAMP4 granted stock options to new employees.
  • Inducement grants aim to attract talent.
  • Stock options have a ten-year term.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~45 mo
Low dilution risk
Lead asset
CMP-002
Phase 2 · Nervous System Disease

Full Press Release Details

WATERTOWN, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on November 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 30,000 shares of the Company’s common stock to two newly hired employees of the Company, each as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).
The Inducement Grants each have a ten-year term and an exercise price per share of $3.86, which is equal to the closing price of CAMP4’s common stock as of the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement.
About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.

Investor Relations: Sara Michelmore Milestone Advisors sara@milestone-advisorsllc.com

Media: Sofia Bermudez LifeSci Communications sbermudez@lifescicomms.com

Frequently Asked Questions

What is the purpose of the inducement grant?

The inducement grant aims to attract new talent to CAMP4 Therapeutics.

How many shares were granted to each employee?

Each employee received stock options for 30,000 shares.

What is the exercise price of the stock options?

The exercise price is set at $3.86 per share.

What is the vesting schedule for the stock options?

The options will vest over four years, with 25% vesting after one year.

Last updated: Nov 17, 2026